Company intelligence / Profile preview
PDS Biotech
Princeton, New Jersey, United Statespdsbiotech.com ↗
- Ownership
- Public · PDSB
- Employees
- ~15
- Development stage
- Phase 3
01
Overview
PDS Biotech’s lead program Versamune® HPV in combination with pembrolizumab has advanced to a global Phase 3 trial for first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer. The company received FDA Fast Track designation for this combination. Previous studies showed strong and durable clinical responses. Additional pipeline programs include a novel IL‑12 antibody-drug conjugate targeting the tumor microenvironment in colorectal cancer now entering clinical trials.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineAntibody-drug conjugateProteinImmunotherapy
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $65.3M
- Total revenue
- $0
- Enterprise value
- $64.1M
Beyond the preview
Go deeper on PDS Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDS Biotech.